Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: prophylaxis vs. pre-emptive strategies for prevention.
作者信息
Worth Leon J, Thursky Karin A
机构信息
Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
出版信息
Leuk Lymphoma. 2006 Dec;47(12):2435-6. doi: 10.1080/10428190601090436.
PMID:17169785
Abstract
摘要
相似文献
1
Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: prophylaxis vs. pre-emptive strategies for prevention.
Leuk Lymphoma. 2006 Dec;47(12):2435-6. doi: 10.1080/10428190601090436.
2
Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
Haematologica. 2004 Oct;89(10):1248-52.
3
The prevention of alemtuzumab-induced cytomegalovirus reactivation: still a matter of debate. An update from Pesaro experience with once weekly intravenous ganciclovir.
Leuk Lymphoma. 2009 Feb;50(2):294-6. doi: 10.1080/10428190802627580.
4
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.
Blood. 2008 Feb 15;111(4):1816-9. doi: 10.1182/blood-2007-03-080010. Epub 2007 Nov 26.
5
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
J Clin Oncol. 2006 May 20;24(15):2337-42. doi: 10.1200/JCO.2005.04.6037. Epub 2006 Apr 17.
6
An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab.
Leuk Lymphoma. 2006 Dec;47(12):2542-6. doi: 10.1080/10428190600929311.
7
Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?
Blood. 2008 Sep 1;112(5):2167. doi: 10.1182/blood-2008-05-155465.
8
Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
Expert Rev Hematol. 2011 Feb;4(1):9-16. doi: 10.1586/ehm.10.77.
9
Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
Clin Lymphoma. 2002 Sep;3(2):105-10. doi: 10.3816/clm.2002.n.016.
10
Progress with alemtuzumab in chronic lymphocytic leukemia: Update from the 2003 meeting of the american society of hematology.
Clin Lymphoma. 2004 Mar;4(4):217-9. doi: 10.1016/s1526-9655(11)70036-7.
Zotero 插件